Borean Pharma receives Notice of Allowance of HIV drug patent by U.S. Patent & Trademark Office

25-Oct-2007

Borean Pharma, ApS announced that it has received a Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) in connection with Borean's patent application for Human immunodeficiency Virus (HIV) fusion inhibitors for treating AIDS. The USPTO has stated that it intends to grant patent protection which covers six proprietary drug candidates capable of inhibiting HIV from infecting human cells. The patent is expected to expire in 2025.

Borean's HIV drug candidates are trimeric fusion proteins. These represent a next generation in HIV fusion inhibitors that are expected to combine greater patient safety and convenience with lower production and treatment costs.

"HIV remains one of the greatest challenges for medicine and this patent is therefore tremendously important to us," stated Dr. Johanna Holldack, CEO of Borean Pharma. "The acceptance of this patent is a significant milestone for Borean Pharma because it continues to solidify the positioning of our technologies and products."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances